Literature DB >> 9734364

A new role for hypoxia in tumor progression: induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs.

A Coquelle1, F Toledo, S Stern, A Bieth, M Debatisse.   

Abstract

Genome rearrangements including gene amplification are frequent properties of tumor cells, but how they are related to the tumor microenvironment is unknown. Here, we report direct evidence for a causal relationship between hypoxia, induction of fragile sites, and gene amplification. Recently, we showed that breaks at fragile sites initiate intrachromosomal amplification. We demonstrate here that hypoxia is a potent fragile site inducer and that, like fragile sites inducing drugs, it drives fusion of double minutes (DMs) and their targeted reintegration into chromosomal fragile sites, generating homogeneously staining regions (HSRs). This pathway operates efficiently for DMs bearing different sequences, suggesting a model of hypoxia-driven formation of the HSRs containing nonsyntenic sequences frequently observed in solid tumors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9734364     DOI: 10.1016/s1097-2765(00)80137-9

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  76 in total

1.  Enhanced flexibility and aphidicolin-induced DNA breaks near mammalian replication origins: implications for replicon mapping and chromosome fragility.

Authors:  F Toledo; A Coquelle; E Svetlova; M Debatisse
Journal:  Nucleic Acids Res       Date:  2000-12-01       Impact factor: 16.971

Review 2.  Tumor hypoxia and genetic alterations in sporadic cancers.

Authors:  Minoru Koi; Clement R Boland
Journal:  J Obstet Gynaecol Res       Date:  2011-01-27       Impact factor: 1.730

3.  Structure of a palindromic amplicon junction implicates microhomology-mediated end joining as a mechanism of sister chromatid fusion during gene amplification.

Authors:  Yukiko Okuno; Peter J Hahn; David M Gilbert
Journal:  Nucleic Acids Res       Date:  2004-02-02       Impact factor: 16.971

4.  Molecular structure of double-minute chromosomes bearing amplified copies of the epidermal growth factor receptor gene in gliomas.

Authors:  Nicolas Vogt; Sandrine-Hélène Lefèvre; Françoise Apiou; Anne-Marie Dutrillaux; Andrej Cör; Pascal Leuraud; Marie-France Poupon; Bernard Dutrillaux; Michelle Debatisse; Bernard Malfoy
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-21       Impact factor: 11.205

5.  Hypoxic stress facilitates acute activation and chronic downregulation of fanconi anemia proteins.

Authors:  Susan E Scanlon; Peter M Glazer
Journal:  Mol Cancer Res       Date:  2014-03-31       Impact factor: 5.852

6.  Architectures of somatic genomic rearrangement in human cancer amplicons at sequence-level resolution.

Authors:  Graham R Bignell; Thomas Santarius; Jessica C M Pole; Adam P Butler; Janet Perry; Erin Pleasance; Chris Greenman; Andrew Menzies; Sheila Taylor; Sarah Edkins; Peter Campbell; Michael Quail; Bob Plumb; Lucy Matthews; Kirsten McLay; Paul A W Edwards; Jane Rogers; Richard Wooster; P Andrew Futreal; Michael R Stratton
Journal:  Genome Res       Date:  2007-08-03       Impact factor: 9.043

Review 7.  An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy.

Authors:  R G Bristow; A Berlin; A Dal Pra
Journal:  Br J Radiol       Date:  2014-02-03       Impact factor: 3.039

8.  Cancer Stem Cells under Hypoxia as a Chemoresistance Factor in Breast and Brain.

Authors:  Spencer W Crowder; Daniel A Balikov; Yu-Shik Hwang; Hak-Joon Sung
Journal:  Curr Pathobiol Rep       Date:  2014-03

9.  The anti-protozoan drug nifurtimox preferentially inhibits clonogenic tumor cells under hypoxic conditions.

Authors:  Quhuan Li; Qun Lin; Hoon Kim; Zhong Yun
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

10.  E2F6 inhibits cobalt chloride-mimetic hypoxia-induced apoptosis through E2F1.

Authors:  Wei-Wei Yang; Bo Shu; Yi Zhu; Huang-Tian Yang
Journal:  Mol Biol Cell       Date:  2008-06-18       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.